Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas

PURPOSE: Anlotinib is a novel tyrosine kinase inhibitor with promising anti-tumor activity in patients with advanced soft tissue sarcomas (STS) in China. Liposomal doxorubicin monotherapy showed an encouraging effect on this disease. The aim of this study was to evaluate the efficacy and safety of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhiyong, Yao, Weitao, Zhao, Yao, Liu, Oufei, Zhang, Peng, Ge, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871875/
https://www.ncbi.nlm.nih.gov/pubmed/33574700
http://dx.doi.org/10.2147/CMAR.S286322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871875/
https://www.ncbi.nlm.nih.gov/pubmed/33574700
http://dx.doi.org/10.2147/CMAR.S286322

Ejemplares similares